Engineering the Immune System
“Immunoengineering is applying engineering principles to the discovery and design of the immune system,” says biomedical engineer Jordan Green, one of several faculty members leading the charge in this area at Johns Hopkins. “This is a really new territory for us. These two different worlds historically haven’t intersected that much.”
Immunologists develop therapies that focus on fundamental mechanistic biology, adds pathology researcher Jonathan Schneck, while engineers tend to design treatments that, until now, simply don’t take into consideration the immune system. “Ideally, therapies, including engineering-based approaches, should harness the immune system and benefit from engineering optimization.”
Combining the know-how from both fields could lead to advances in a number of medical areas, says Schneck, such as enhancing tissue regeneration, regulating tolerance and biocompatibility of medical implants, controlling infectious diseases and boosting the potency of vaccines, and reducing inflammation for improvement of heart disease.
Just this past year, immunoengineering became a recognized term at the National Institutes of Health program office, says Green: “It’s really at the frontier of a lot of areas—whether it’s cell engineering, tissue engineering, cancer therapy, biomaterials, diabetes, implants or transplantation—where having control, precision, and safety and efficacy of immune system interactions is really critical.” Green has added a lecture about immunoengineering to a course on cell engineering he teaches at Johns Hopkins to advanced undergraduate and graduate students. The departments of Biomedical Engineering and Chemical and Biomolecular Engineering just recruited a new faculty member from Stanford University, Jamie Spangler, with expertise in immunoengineering and protein engineering.
How immunoengineering emerged at Johns Hopkins is “a classic Hopkins story.” It started from the ground up by students, Schneck says. Joel Sunshine, a former student Schneck taught during medical school and who was conducting research in Green’s lab while a medical student, was interested in committing himself further to research. Sunshine was admitted to the M.D./Ph.D. program at Johns Hopkins and decided to continue in Green’s lab but was interested in collaborative opportunities with Schneck. About a year and half into his Ph.D., Sunshine came back to Schneck and said he liked Schneck’s work developing artificial antigen presenting cells, or aAPC (a particle based approach that mimics natural antigen presenting cells that activate or repress the immune system). Sunshine was intrigued by the engineering that went into this work because it was complementarity to his particle engineering research in the Green lab. Sunshine had an idea about a collaborative project to redesign parts of the artificial APC. “I told Joel to talk to Karlo Perica, another M.D./Ph.D. student in my lab, and work on something,” Schneck says. “That’s the way the project started.”
In 2013, in the journal Biomaterials the two labs published a paper demonstrating that football-shaped artificial cells did a better job than the typical round cells in teaching immune cells to recognize and destroy cancer cells in mice. Fortuitously published during football season, it garnered some press attention. Green and Schneck have continued to work together, publishing several papers since. “I love telling this story,” says Schneck, “because I think it perfectly captures our culture here at Johns Hopkins.”
Green has been developing novel, biodegradable nanomaterials that could be used in cells to deliver instructions telling them how to behave. Other researchers at Johns Hopkins working on immunoengineering projects include biomedical engineer Jennifer Elisseeff, Ph.D., director of the Translational Tissue Engineering Center, who is working on the development of new materials targeting the immune response and regenerative T cell therapy to facilitate wound healing, and oncologist Jonathan Powell, M.D., Ph.D., associate director of the new Bloomberg-Kimmel Institute for Cancer Immunotherapy, who is working to metabolically engineer cells to maximize therapeutic potential in wound healing and cancer immunotherapy. Materials engineer Hai-Quan Mao, associate director of the Institute for NanoBioTechnology, has been involved in immunoengineering education and training. A Discovery Award from Johns Hopkins has helped foster their coming together as a group.
Excerpted from Johns Hopkins Medicine.